Sana Biotechnology, Inc. Proceeds from Sale of Productive Assets
Sana Biotechnology, Inc. (SANA) reported Proceeds from Sale of Productive Assets of $271.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2026-08-10
- Sana Biotechnology, Inc. proceeds from sale of productive assets for the quarter ending 2026-06-30 was $23.00K, a 93.98% decline year-over-year.
- Sana Biotechnology, Inc. proceeds from sale of productive assets for the quarter ending 2026-03-31 was $248.00K, a 1.98% decline year-over-year.
- Sana Biotechnology, Inc. proceeds from sale of productive assets for the quarter ending 2025-12-31 was $661.00K.
- Sana Biotechnology, Inc. proceeds from sale of productive assets for the quarter ending 2025-09-30 was $136.00K.
- Sana Biotechnology, Inc. proceeds from sale of productive assets for fiscal 2025 was $1.43M.
- Sana Biotechnology, Inc. proceeds from sale of productive assets for fiscal 2024 was $0.00.
- Sana Biotechnology, Inc. proceeds from sale of productive assets for fiscal 2023 was $0.00.
| Period end | Proceeds from Sale of Productive Assets 3 month | Proceeds from Sale of Productive Assets 6 month | Proceeds from Sale of Productive Assets 9 month | Proceeds from Sale of Productive Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $271.00K 10-Q · filed 2026-08-10 | $932.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.07M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $248.00K 10-Q · filed 2026-05-11 | $909.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.04M derived: sum of 3 quarters · filed 2026-05-11 | $1.43M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $661.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $797.00K derived: sum of 2 quarters · filed 2026-03-03 | $1.18M derived: sum of 3 quarters · filed 2026-08-10 | $1.43M 10-K · filed 2026-03-03 |
| 2025-09-30 | $136.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $518.00K derived: sum of 2 quarters · filed 2026-08-10 | $771.00K 10-Q · filed 2025-11-06 | $771.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $382.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $635.00K 10-Q · filed 2026-08-10 | $635.00K derived: sum of 3 quarters · filed 2026-08-10 | $635.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $253.00K 10-Q · filed 2026-05-11 | $253.00K derived: sum of 2 quarters · filed 2026-05-11 | $253.00K derived: sum of 3 quarters · filed 2026-05-11 | $253.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 derived: sum of 3 quarters · filed 2026-03-03 | $0.00 10-K · filed 2026-03-03 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $0.00 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |